Skip to main content
SpringerLink
Log in

Imaging and Therapy of Neuroendocrine Tumors of the Abdomen

  • Chapter
Diseases of the Abdomen and Pelvis 2014–2017

  • 1086 Accesses

Abstract

THERANOSTICS is an acronym that exemplifies the inseparability of diagnostics and therapeutics in the individualized management of disease. Neuroendocrine tumors (NETs) express somatostatin receptors (SSTRs), enabling the use of somatostatin (SMS) analogs for molecular imaging, when labeled with the positron emitter gallium- 68 (68Ga) for receptor positron emission tomography computed tomography (PET/CT) and targeted radionuclide therapy when labeled with beta-emitters 90Y and 177Lu (Fig. 1). Peptide receptor radionuclide therapy (PRRT) using 90Y- and 177Lu-labeled SMS analogs or a combination of the two (DUO-PRRT) is highly effective in the management of advanced or progressive NETs. Apart from benefit in overall survival from time of diagnosis of several years, significant improvement in clinical symptoms and excellent palliation can be achieved. In patients with progressive NETs, fractionated, personalized PRRT with lower doses of radioactivity given over a longer period of time results in good therapeutic responses.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Modlin IM, Oberg K, Chung DC et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9:61–72.

    Article  CAS  PubMed  Google Scholar 

  2. Rufini V, Baum RP, Castaldi P et al (2012) Role of PET/CT in the functional imaging of endocrine pancreatic tumors. Abdom Imaging 37:1004–1020.

    Article  PubMed  Google Scholar 

  3. Baum RP, Prasad V (2008) PET and PET/CT imaging of neuroendocrine tumors. In: Wahl R, Beansland RSB (2008) Principles and practice of PET and PET/CT. Lippincott and Williams, Philadelphia, PA.

    Google Scholar 

  4. Krenning EP, Kwekkeboom DJ, Bakker WH et al (1993) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716–731.

    Article  CAS  PubMed  Google Scholar 

  5. Decristoforo C, Melendez-Alafort L, Sosabowski JK et al (2000) 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide. J Nucl Med 41:1114–1119.

    CAS  PubMed  Google Scholar 

  6. Baum RP, Kulkarni HR, Carreras C (2012) Peptides and receptors in image-guided therapy: THERANOSTICS for neuroendocrine neoplasms. Semin Nucl Med 42:190–207.

    Article  PubMed  Google Scholar 

  7. Hofmann M, Maecke H, Borner R et al (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med Mol Imaging 28:1751–1757.

    Article  CAS  Google Scholar 

  8. Buchmann I, Henze M, Engelbrecht S et al (2007) Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34:1617–1626.

    Article  CAS  PubMed  Google Scholar 

  9. Kaemmerer D, Peter L, Lupp A et al (2011) Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 8:1659–1668.

    Article  Google Scholar 

  10. Prasad V, Ambrosini V, Hommann M (2010) Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 37:67–77.

    Article  CAS  PubMed  Google Scholar 

  11. Shapiro B, Copp JE, Sisson JC et al (1985) Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 26:576–585.

    CAS  PubMed  Google Scholar 

  12. Gazdar AF, Helman LJ, Israel MA et al (1988) Expression of neuroendocrine cell markers L-DOPA decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res 48:4078–4082.

    CAS  PubMed  Google Scholar 

  13. Kolby L, Bernhardt P, Levin-Jakobsen AM et al (2003) Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. Br J Cancer 89:1383–1388.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Kayani I, Bomanji JB, Groves A et al (2008) Functional imaging of neuroendocrine tumours with combined PET/CT using 240 68Ga-DOTATATE (Dota-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 112:2447–2455.

    Article  PubMed  Google Scholar 

  15. Kwekkeboom DJ, Mueller-Brand J, Paganelli G et al (2005) Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46:62S–66S.

    CAS  PubMed  Google Scholar 

  16. Bodei L, Cremonesi M, Grana C et al (2004) Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90YDOTATOC) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 31:1038–1046.

    Article  CAS  PubMed  Google Scholar 

  17. Khan S, Krenning EP, van Essen M et al (2011) Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med 52:1361–1368.

    Article  CAS  PubMed  Google Scholar 

  18. Kwekkeboom DJ, de Herder WW, Kam BL et al (2008) Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26:2124–2130.

    Article  CAS  PubMed  Google Scholar 

  19. Imhof A, Brunner P, Marincek N et al (2011) Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 29:2416–2423.

    Article  CAS  PubMed  Google Scholar 

  20. Anlauf M, Gerlach P, Raffel A et al (2011) Neuroendocrine neoplasia of the gastroenteropancreatic system. Pathology and classification. Onkologe 17:572–582.

    Article  Google Scholar 

  21. Bodei L, Mueller-Brand J, Baum RP et al (2013) The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 40:800–816.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Valkema R, Pauwels SA, Kvols LK et al (2005) Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA(0),Tyr(3)-octreotide and 177Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 46:83S–91S.

    CAS  PubMed  Google Scholar 

  23. Rolleman EJ, Valkema R, de Jong M et al (2003) Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 30:9–15.

    Article  CAS  PubMed  Google Scholar 

  24. Hörsch D, Bert T, Schrader J et al (2012) Pancreatic neuroendocrine neoplasms. Minerva Gastroenterol Dietol 58:401–426.

    PubMed  Google Scholar 

  25. de Jong M, Breeman WA, Valkema R et al (2005) Combination radionuclide therapy using 177Lu-and 90Y-labeled somatostatin analogs. J Nucl Med 46:13S–7S.

    PubMed  Google Scholar 

  26. Kunikowska J, Królicki L, Hubalewska-Dydejczyk A et al (2011) Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging 38:1788–1797.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Limouris GS, Chatziioannou A, Kontogeorgakos D et al (2008) Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging 35:1827–1837.

    Google Scholar 

  28. Claringbold PG, Brayshaw PA, Price RA et al (2011) Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 38:302–311.

    Article  CAS  PubMed  Google Scholar 

  29. Kaemmerer D, Prasad V, Daffner W et al (2009) Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol 15:5867–5870.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany

    Richard P. Baum & Harshad R. Kulkarni

Authors
  1. Richard P. Baum
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harshad R. Kulkarni
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Radiology, University Hospital, Zurich, Switzerland

    J. Hodler

  2. Nuclear Medicine, University Hospital, Zurich, Switzerland

    G. K. von Schulthess

  3. Radiology, Kantonsspital, Baden, Switzerland

    R. A. Kubik-Huch

  4. Kilchberg/Zurich, Switzerland

    Ch. L. Zollikofer

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Italia

About this chapter

Cite this chapter

Baum, R.P., Kulkarni, H.R. (2014). Imaging and Therapy of Neuroendocrine Tumors of the Abdomen. In: Hodler, J., von Schulthess, G.K., Kubik-Huch, R.A., Zollikofer, C.L. (eds) Diseases of the Abdomen and Pelvis 2014–2017. Springer, Milano. https://doi.org/10.1007/978-88-470-5659-6_30

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-5659-6_30

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-5658-9

  • Online ISBN: 978-88-470-5659-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation